Ignacio Durán
Impact in
Papers in
-
- Renal cell carcinoma treatment 29
- Prostate Cancer Treatment and Research 21
- Surgery 68
- Bladder and Urothelial Cancer Treatments 53
- Testicular diseases and treatments 13
- Co-authors
- Daniel Castellano (25 shared papers)Thomas B. Powles (17 shared papers)Yohann Loriot (14 shared papers)Carmen Garrigós (5 shared papers)Saman Maleki Vareki (2 shared papers)Jonathan E. Rosenberg (7 shared papers)Daniel Peter Petrylak (5 shared papers)Nobuaki Matsubara (3 shared papers)
- Journals
- Annals of Oncology (24 papers)Clinical & Translational Oncology (17 papers)European Urology (14 papers)Clinical Genitourinary Cancer (8 papers)European Journal of Cancer (6 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Ignacio Durán
170 papers receiving 12.7k citations
Ignacio Durán's Hit Papers
Peers
Comparison fields: 5 of 121
- Oncology 3.6k
- Surgery 5.1k
- Pulmonary and Respiratory Medicine 2.5k
- Cancer Research 652
- Radiology, Nuclear Medicine and Imaging 465
Countries citing papers authored by Ignacio Durán
This map shows the geographic impact of Ignacio Durán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Durán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Durán more than expected).
Fields of papers citing papers by Ignacio Durán
This network shows the impact of papers produced by Ignacio Durán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Durán. The network helps show where Ignacio Durán may publish in the future.
Co-authors
The 25 scholars most cited alongside Ignacio Durán, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 177 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2016 | 1820 |
| 2 | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Hit paper breakdown → | 2017 | 1147 |
| 3 | Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma Hit paper breakdown → | 2019 | 1066 |
| 4 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Hit paper breakdown → | 2021 | 895 |
| 5 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Hit paper breakdown → | 2019 | 657 |
| 6 | Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Hit paper breakdown → | 2024 | 628 |
| 7 | Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Hit paper breakdown → | 2019 | 466 |
| 8 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 408 |
| 9 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 Hit paper breakdown → | 2020 | 309 |
| 10 | 2006 | 276 | |
| 11 | 2017 | 262 | |
| 12 | 2017 | 231 | |
| 13 | 2014 | 181 | |
| 14 | Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder Hit paper breakdown → | 2022 | 159 |
| 15 | 2017 | 140 | |
| 16 | 2017 | 138 | |
| 17 | Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study Hit paper breakdown → | 2022 | 138 |
| 18 | 2006 | 133 | |
| 19 | Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium Hit paper breakdown → | 2021 | 130 |
| 20 | Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 Hit paper breakdown → | 2023 | 127 |
About Ignacio Durán
Ignacio Durán is a scholar working on Pulmonary and Respiratory Medicine, Surgery, Oncology, Cancer Research and Internal Medicine, having authored 177 papers that have together received 13k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (53 papers), Renal cell carcinoma treatment (29 papers), Prostate Cancer Treatment and Research (21 papers), Cancer Immunotherapy and Biomarkers (17 papers), Testicular diseases and treatments (13 papers), Bone health and treatments (13 papers), Multiple Sclerosis Research Studies (5 papers) and Neuroendocrine Tumor Research Advances (5 papers). The work is most often cited by research in Oncology (3.6k citations), Surgery (5.1k citations), Pulmonary and Respiratory Medicine (2.5k citations), Cancer Research (652 citations) and Radiology, Nuclear Medicine and Imaging (465 citations). Ignacio Durán has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Daniel Castellano, Thomas B. Powles, Yohann Loriot, Carmen Garrigós, Saman Maleki Vareki, Jonathan E. Rosenberg, Daniel Peter Petrylak, Nobuaki Matsubara, Christof Vulsteke and Mary S. Campbell. Their work appears in journals such as Annals of Oncology, Clinical & Translational Oncology, European Urology, Clinical Genitourinary Cancer and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.